Fusion Pharmaceuticals Inc. (NASDAQ:FUSN – Free Report) – Analysts at Leerink Partnrs issued their Q1 2024 earnings per share (EPS) estimates for Fusion Pharmaceuticals in a note issued to investors on Monday, January 29th. Leerink Partnrs analyst F. Khurshid expects that the company will post earnings per share of ($0.32) for the quarter. The consensus […]
Fusion Pharmaceuticals (NASDAQ:FUSN – Get Free Report) and Atara Biotherapeutics (NASDAQ:ATRA – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, profitability, valuation, dividends and risk. Risk and Volatility Fusion Pharmaceuticals has a […]
Fusion Pharmaceuticals Inc. (NASDAQ:FUSN – Get Free Report)’s share price hit a new 52-week high on Thursday . The stock traded as high as $10.64 and last traded at $10.30, with a volume of 223577 shares changing hands. The stock had previously closed at $10.03. Analysts Set New Price Targets A number of equities research […]
Shares of Fusion Pharmaceuticals Inc. (NASDAQ:FUSN – Get Free Report) gapped down before the market opened on Monday . The stock had previously closed at $9.12, but opened at $8.75. Fusion Pharmaceuticals shares last traded at $9.25, with a volume of 63,888 shares traded. Wall Street Analyst Weigh In FUSN has been the subject of […]
Fusion Pharmaceuticals (NASDAQ:FUSN – Get Free Report)‘s stock had its “outperform” rating reissued by stock analysts at William Blair in a research report issued on Friday, RTT News reports. Other analysts have also recently issued research reports about the company. Royal Bank of Canada started coverage on Fusion Pharmaceuticals in a research report on Wednesday, […]